| Market Capitalization (Millions $) |
1,714 |
| Shares
Outstanding (Millions) |
90 |
| Employees |
175 |
| Revenues (TTM) (Millions $) |
114 |
| Net Income (TTM) (Millions $) |
125 |
| Cash Flow (TTM) (Millions $) |
0 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Omeros Corporation is a biopharmaceutical company that is headquartered in Seattle, Washington. The company is focused on identifying, developing, and commercializing therapeutics for a range of medical conditions that affect the eye, as well as the central nervous system (CNS), and immune-mediated diseases.
The company's lead product candidates are OMS302, OMS721, and OMS82 OMS302 is designed for use during cataract surgery and is a combination of two drugs - phenylephrine and ketorolac - that are intended to reduce inflammation, inhibit pupil constriction, and provide pain relief. OMS721 is an investigational human monoclonal antibody that targets a protein called MASP-2, which is believed to be involved in the development of certain renal and hematologic disorders. And OMS824 is being developed as a potential treatment for schizophrenia, Huntington's disease, and other CNS disorders.
In addition to these lead product candidates, Omeros has multiple programs in preclinical and clinical development for a variety of indications, including complement-mediated diseases, addiction, and acute pain.
The company's technology platform involves their proprietary PharmacoSurgery platform, which is designed to provide a unique combination of pharmacology and surgery in one setting. This approach facilitates improved surgical outcomes and reduced recovery times for patients.
Omeros has established relationships with various partners, including surgery centers, pharmaceutical companies, and academic institutions, to facilitate their research and development efforts. They have also received support from government agencies, such as the National Institute of Neurological Disorders and Stroke and the National Institute on Drug Abuse.
Overall, Omeros Corporation is committed to advancing their research and development efforts to meet the unmet needs of patients with a range of medical conditions.
Company Address: 201 Elliott Avenue West Seattle 98119 WA
Company Phone Number: 676-5000 Stock Exchange / Ticker: NASDAQ OMER
|
11.11% 
0.75 %